MarketCapExport financials
Vapotherm (VAPO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Vapotherm Cash Flow 2023-2011 | VAPO
Brief overview of Vapotherm's cash flow quality
The review uses the five latest available annual reports between 2019 and 2023.
Operating cash flow is negative at -$24.3 million, leaving internal funding capacity weak.
Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.
Cash from operations as a share of revenue increased from -82.5% to -35.3%, improving cash efficiency.
An additional $14.6 million became tied up in estimated working capital, equal to 21.2% of revenue.
Overall picture
Vapotherm has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.
Annual Cash Flow Vapotherm
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-24.3 M | -80.2 M | -55.4 M | -39.5 M | -39.7 M | -40 M | - | - | - | - | - | - | - |
Depreciation & Amortization |
4.98 M | 5.18 M | 5.65 M | 4.77 M | 3.08 M | 2.17 M | - | - | - | - | - | - | - |
Accounts Payables |
5.05 M | 2.74 M | 5.92 M | 4.97 M | 3.38 M | 3.15 M | - | - | - | - | - | - | - |
Accounts Receivables |
10.7 M | 9.1 M | 10.9 M | 23.5 M | 8.24 M | 7.11 M | - | - | - | - | - | - | - |
Total Inventories |
23 M | 33 M | 36.6 M | 19.9 M | 9.14 M | 13.7 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Vapotherm
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-9.83 M | -6.56 M | - | -20.3 M | -17.4 M | -10 M | - | -69.3 M | -50.1 M | -30.5 M | - | -39.2 M | -30.4 M | -20 M | - | -32.1 M | -24.7 M | -10.7 M | - | -28.5 M | -18.9 M | -9.83 M | - | -28.6 M | -17.1 M | -10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
2.53 M | 1.31 M | - | 3.69 M | 2.44 M | 1.25 M | - | 4.01 M | 2.74 M | 1.39 M | - | 4.18 M | 2.86 M | 1.57 M | - | 3.37 M | 2.15 M | 1.1 M | - | 2.22 M | 700 K | 621 K | - | 1.56 M | 500 K | 466 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
4.38 M | 4.3 M | 5.05 M | 2.95 M | 2.16 M | 2.97 M | 2.74 M | 1.51 M | 3.47 M | 6.61 M | 5.92 M | 4.14 M | 5.09 M | 6.05 M | 4.97 M | 6.25 M | 6.79 M | 4.61 M | 3.38 M | 1.64 M | 1.57 M | 1.51 M | 3.15 M | 3.15 M | 3.15 M | 3.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
8.56 M | 10.2 M | 10.7 M | 7.44 M | 8.92 M | 8.4 M | 9.1 M | 8.14 M | 7.05 M | 9.91 M | 10.9 M | 20.8 M | 8.5 M | 13.7 M | 23.5 M | 10.9 M | 16.5 M | 11.9 M | 8.24 M | 6.85 M | 7.3 M | 6.66 M | 7.11 M | 7.11 M | 7.11 M | 7.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
23.3 M | 24.1 M | 23 M | 23.1 M | 25.1 M | 28.5 M | 33 M | 36.4 M | 38.4 M | 38 M | 36.6 M | 24.7 M | 29.4 M | 26.9 M | 19.9 M | 25 M | 18.6 M | 9.1 M | 9.14 M | 10.8 M | 11.2 M | 12.4 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Vapotherm, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Venus Concept
VERO
|
- | - | $ 726 K |  USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Aethlon Medical
AEMD
|
$ 5.15 | 0.57 % | $ 3.47 M | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Abiomed
ABMD
|
- | - | $ 17.2 B | USA |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M |  Canada |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
LivaNova PLC
LIVN
|
$ 77.58 | 0.01 % | $ 4.23 B |  Britain |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
LENSAR
LNSR
|
$ 5.8 | 1.0 % | $ 69.4 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Pulmonx Corporation
LUNG
|
$ 1.78 | 3.93 % | $ 72.4 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.16 | 3.22 % | $ 19.6 M | USA |
 |
Zynex
ZYXI
|
- | - | $ 21.1 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M |  Israel |
 |
Align Technology
ALGN
|
$ 147.31 | 0.83 % | $ 10.7 B | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.55 | 0.39 % | $ 105 M | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.39 | 0.53 % | $ 65.7 B | USA |
 |
Bio-Rad Laboratories
BIO
|
$ 353.7 | 0.71 % | $ 9.64 B | USA |
 |
ClearPoint Neuro
CLPT
|
$ 9.07 | 4.33 % | $ 257 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
InspireMD
NSPR
|
$ 0.46 | 0.29 % | $ 29.6 M | Israel |
 |
Butterfly Network
BFLY
|
$ 7.25 | 3.43 % | $ 1.79 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | Britain |
 |
Outset Medical
OM
|
$ 3.94 | 0.86 % | $ 59.9 K | USA |
 |
AxoGen
AXGN
|
$ 34.62 | 1.39 % | $ 1.59 B | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
PAVmed
PAVM
|
$ 2.41 | 2.58 % | $ 1.62 M | USA |
 |
Profound Medical Corp.
PROF
|
$ 6.01 | 0.24 % | $ 182 M | Canada |
 |
Quanterix Corporation
QTRX
|
$ 2.87 | 0.33 % | $ 122 M | USA |
 |
AVITA Medical
RCEL
|
$ 13.04 | 2.37 % | $ 363 M |  Australia |
 |
CONMED Corporation
CNMD
|
$ 46.72 | 0.19 % | $ 1.45 B | USA |